Immatics Biotechnologies GmbH
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.immatics.com
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 145
- Registration Number
- NCT05958121
- Locations
- 🇳🇱
Antoni von Leeuwenhoek- Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands
🇩🇪Universitaetsklinikum Ulm AöR, Ulm, Baden-Wuerttemberg, Germany
🇩🇪Universitaetsklinikum Erlangen AöR, Erlangen, Bavaria, Germany
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 50
- Registration Number
- NCT05359445
- Locations
- 🇩🇪
Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten, Heidelberg, Baden-Wurttemberg, Germany
🇩🇪Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I, Freiburg, Baden-Wurttemberg, Germany
🇩🇪Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen, Tuebingen, Baden-Wurttemberg, Germany
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT02149225
- Locations
- 🇳🇱
Leiden University Medical Center, Department of Medical Oncology, Leiden, Netherlands
🇨ðŸ‡Hôpitaux Universitaires de Genève, Geneva 14, Switzerland
🇩🇰Rigshospitalet, The Finsen Centre, Department of Oncology, Copenhagen, Denmark
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
- Conditions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT01403285
- Locations
- 🇺🇸
Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 339
- Registration Number
- NCT01265901
- Locations
- 🇷🇴
Medisprof SRL, Cluj-Napoca, Romania
🇺🇸Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
- Conditions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 92
- Registration Number
- NCT00785122
- Locations
- ðŸ‡ðŸ‡º
University of Szeged, Department of Oncotherapy, Szeged, Hungary
ðŸ‡ðŸ‡ºSt. Gyorgy County Hospital, Székesfehérvár, Hungary
🇬🇧The Royal Sussex County Hospital, CIR-Unit, Brighton, United Kingdom
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
- Conditions
- Interventions
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT00523159
- Locations
- ðŸ‡ðŸ‡º
BAZ megyei Kórház - Urológia Osztály, Miskolc, Hungary
🇩🇪Universitätsklinikum Heidelberg - Klinik für Urologie, Heidelberg, Germany
ðŸ‡ðŸ‡ºPécs Orvostudomanyi Egyetem - Urológiai Klinika, Pécs, Hungary